Abbott Highlights the Five Presentations of Minimally Invasive Structural Heart Technologies for Heart Diseases at TCT 2022
Shots:
- The 5 presentations highlight the impact of structural heart devices to repair or replace heart valves & close openings in the heart
- In (EXPAND G4) study, the MitraClip G4 system showed 91% MR reduction, lowest AEs rates with 1.3% all-cause mortality @30 days along with clinical improvements, 83% achieved NYHA functional class I/II; 52% points from a baseline of 31%; 18-point improvement in KCCQ score; 35% from baseline score
- In (TRILUMINATE) trial, TriClip for TR showed a 99% high implant success rate, 1-grade TR reduction (91%) with residual TR in 74%, 17-point improvement in KCCQ score; 30% from baseline score showed improvement in QoL. The results also demonstrate the benefits of Amulet for stroke reduction in patients with AF & Portico for AS
Ref: PRNewswire| Image: Abbott
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
